Cefotiam mechanism of action

Cefotiam is a parenteral second-generation cephalosporin antibiotic. It has broad-spectrum action adjoin Gram-positive and Gram-negative bacteria. As a beta-lactam, its antibacterial action after-effects from the inhibition of corpuscle bank amalgam via affection for penicillin-binding proteins.

Cefotiam was launched as Pansporin in February 1981 by Takeda Pharmaceutical of Japan and has been accessible as a all-encompassing back February 1993.

Cefotiam inhibits final cross-linking date of peptidoglycan production, appropriately inhibiting bacterial corpuscle bank synthesis. It has agnate or beneath action adjoin Gram-positive staphylococci and streptococci, but is aggressive to some beta-lactamases produced by Gram-negative bacteria. It is added alive adjoin abounding of the Enterobacteriaceae including Enterobacter, E. coli, Klebsiella, Salmonella and indole-positive Proteus species.

In analytic use, top concentrations of cefotiam are empiric in several tissues (kidney, heart, ear, prostate, and animal tract), as able-bodied as in fluids and secretions (bile, ascitic fluid).